Gilead Sciences Inc., (NASDAQ: GILD), has entered into a strategic partnership with Netherlands-based Merus N.V. (NASDAQ: MRUS) to discover two to three trispecific T-cell engagers in the field of oncology. Merus is set to receive an upfront payment of $56 million, an equity investment worth $25 million, and is eligible for up to $1.5 billion in option and milestone payments, in addition to potential sales royalties.
This collaboration will leverage Merus’s proprietary common light chain (CLC) technology to design full-length human trispecific antibodies. These antibodies are expected to drive robust anti-tumor immune responses, offering improved efficacy and safety compared to current bispecific antibodies.- Flcube.com
